EP4453621A1 — Ws12-releasing contact lens
Assigned to CooperVision International Ltd · Expires 2024-10-30 · 2y expired
What this patent protects
A WS12-releasing contact lens is described as well as method of manufacturing the same. The WS12-releasing contact lens comprises a polymeric lens body and WS12 releasably adhered to the polymeric lens body. The amount of WS12 releasably adhered to the polymeric lens body provide…
USPTO Abstract
A WS12-releasing contact lens is described as well as method of manufacturing the same. The WS12-releasing contact lens comprises a polymeric lens body and WS12 releasably adhered to the polymeric lens body. The amount of WS12 releasably adhered to the polymeric lens body provides a basal tear concentration in lens wearers of 2 µg/ml to 8 µg/ml WS12 after 30 minutes of lens wear. The WS12-releasing contact lens can be used to increase contact lens comfort, reduce eye fatigue, reduce sensations of ocular dryness and impart a pleasant, cooling sensation in the lens wearer without causing stinging or burning upon insertion.
Drugs covered by this patent
- Tryptyr (ACOLTREMON) · Alcon Labs Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.